Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
- 9 February 2009
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 10 (3), 247-257
- https://doi.org/10.1016/s1470-2045(09)70002-6
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal CarcinomaJournal of Clinical Oncology, 2007
- Concurrent Cetuximab and Bevacizumab Therapy in a Murine Orthotopic Model of Anaplastic Thyroid CarcinomaThe Laryngoscope, 2007
- A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancersInvestigational New Drugs, 2006
- Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinasesBritish Journal of Cancer, 2006
- The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 BlockadeClinical Cancer Research, 2005
- A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of Recombinant Human Leukemia Inhibitory Factor (rhuLIF, Emfilermin, AM424) to Prevent Chemotherapy-Induced Peripheral NeuropathyClinical Cancer Research, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSIONJournal of Biopharmaceutical Statistics, 1999
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958